Hangzhou Biotest Biotech Co (SHSE:688767) Total Receivables: ¥89.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688767 Hangzhou Biotest Biotech Co Ltd SHSE:688767
70 GF Score
Price ¥34.50
GF Value ¥26.91
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Hangzhou Biotest Biotech Co Total Receivables?

Hangzhou Biotest Biotech Co SHSE:688767 -5.48% 70 Total Receivables is ¥89.1 Mil as of Mar. 2026. GuruFocus rates SHSE:688767 with a GF Score™ of 70/100 and a GF Value™ of ¥26.91 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Hangzhou Biotest Biotech Co's Total Receivables for the quarter that ended in Mar. 2026 was ¥89.1 Mil.

Hangzhou Biotest Biotech Co Total Receivables Related Terms

Hangzhou Biotest Biotech Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Hangzhou Biotest Biotech Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Biotest Biotech Co Total Receivables Chart

Hangzhou Biotest Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only 155.23 40.43 64.69 101.73 92.81

Hangzhou Biotest Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.64 73.25 86.33 92.81 89.13
SHSE:688767
70GF Score
Hangzhou Biotest Biotech Co Ltd SHSE:688767
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Biotest Biotech Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ¥89.1 Mil mean?
Hangzhou Biotest Biotech Co (SHSE:688767) has a Total Receivables of ¥89.1 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hangzhou Biotest Biotech Co and its competitors.
Is Hangzhou Biotest Biotech Co's Total Receivables too high?
Hangzhou Biotest Biotech Co's current Total Receivables is ¥89.1 Mil. Overall, Hangzhou Biotest Biotech Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Biotest Biotech Co's Total Receivables compare to VRTX and REGN?
Hangzhou Biotest Biotech Co's Total Receivables of ¥89.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hangzhou Biotest Biotech Co and its competitors. Hangzhou Biotest Biotech Co's current Total Receivables is ¥89.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Biotest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co (SHSE:688767) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.91, compared to a current price of ¥34.50 — trading 28.2% above its estimated fair value. The current Total Receivables is ¥89.1 Mil. Hangzhou Biotest Biotech Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Hangzhou Biotest Biotech Co (SHSE:688767), the current Total Receivables is ¥89.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hangzhou Biotest Biotech Co (SHSE:688767) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co stock appears to be overvalued. The current stock price of ¥34.50 is trading 28.2% above its estimated GF Value™ of ¥26.91. GuruFocus considers Hangzhou Biotest Biotech Co to be Modestly Overvalued.

Key valuation signals for SHSE:688767:

  • Total Receivables: ¥89.1 Mil
  • GF Value™: ¥26.91 vs. price of ¥34.50 (28.2% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hangzhou Biotest Biotech Co Business Description

Address No. 17, Futai Road, Zhongtai Street, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311121
Hangzhou Biotest Biotech Co Ltd is engaged in the research and development, manufacturing, sales and service of in vitro diagnostic reagents, raw materials and instruments.
70GF Score

Get the complete analysis for SHSE:688767

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥34.50
Price
¥26.91
GF Value